
Commentary|Articles|October 31, 2026
Lonardi on Overall Survival With Nivolumab/Ipilimumab in MSI-H/dMMR mCRC
Author(s)Sara Lonardi, MD, Sabrina Serani
Sara Lonardi, MD, discusses the final overall survival analysis of CheckMate-8HW from ESMO 2026 and its implications for first-line MSI-H/dMMR mCRC.
Advertisement
Advertisement
At the 2026 European Society for Medical Oncology (ESMO) Congress, Sara Lonardi, MD, presented the final overall survival (OS) analysis of the phase 3 CheckMate-8HW trial (NCT04008030), which evaluated nivolumab (Opdivo) plus ipilimumab (Yervoy) vs nivolumab monotherapy or chemotherapy in patients with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) metastatic colorectal cancer (mCRC).1,2
Related to this article

Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.

Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.

Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.

Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.

Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.

Halfdan Sørbye, MD, PhD, discusses why accurately distinguishing NET G3 from NEC is critical, as the wrong first-line therapy can shorten survival.

Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.
Advertisement
Advertisement

